CLINICAL TRIALS PROFILE FOR VILAZODONE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for vilazodone hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00285376 ↗ | Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response | Completed | Genaissance Pharmaceuticals | Phase 3 | 2006-02-01 | This study is designed to determine the safety and effectiveness of vilazodone for major depressive disorder and to discover genetic markers associated with response. This study will enroll approximately 400 patients. |
| NCT00290914 ↗ | Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder | Completed | Pharmacology Research Institute | Phase 2 | 1969-12-31 | The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression. |
| NCT00644358 ↗ | A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) | Completed | Forest Laboratories | Phase 3 | 2007-12-31 | This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients. |
| NCT00683592 ↗ | Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD) | Completed | Forest Laboratories | Phase 3 | 2008-03-01 | This randomized, double-blind, placebo-controlled, multicenter, 8-week, clinical trial is designed to assess the efficacy and safety of vilazodone and to evaluate genetic biomarkers of treatment response associated with vilazodone use in adult patients diagnosed with MDD by the DSM-IV-TR criteria. |
| NCT01473381 ↗ | Safety and Efficacy of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2011-12-01 | The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder. |
| NCT01473394 ↗ | Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2011-12-01 | The purpose of this study was to further characterize the efficacy, safety, and tolerability of a single fixed dose level of vilazodone compared to placebo in patients with major depressive disorder. |
| NCT01573598 ↗ | Safety and Efficacy of Vilazodone in Major Depressive Disorder | Completed | Forest Laboratories | Phase 4 | 2012-04-01 | Safety and Efficacy of Vilazodone in Major Depressive Disorder |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for vilazodone hydrochloride
Condition Name
Clinical Trial Locations for vilazodone hydrochloride
Trials by Country
Clinical Trial Progress for vilazodone hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for vilazodone hydrochloride
Sponsor Name
